Modulation of a spinal locomotor network by metabotropic glutamate receptors.
We have explored the potential involvement of the three main classes of metabotropic glutamate receptor in the modulation of a spinal locomotor network using tadpoles of the anuran amphibian Xenopus laevis. Selective activation of group I receptors in Xenopus embryos and young larvae using the general group I agonist DHPG [(S)-3,5-dihyroxyphenylglycine] significantly increased the frequency of swimming and the number of spontaneously occurring swimming episodes, as monitored by extracellular recordings from ventral roots. Group I receptor activation was without significant effect on the duration or amplitude of motor bursts, the duration of swimming episodes, or the head-to-tail delay in the propagation of swimming activity. Activation of either group II or group III receptors, however, following bath applications of the specific agonists APDC [(2R,4R)-aminopyrrolidine-2,4-dicarboxylic acid] and L-AP4 (L-2-amino-4-phosphonobutanoate), respectively, produced a net inhibitory effect on many of the parameters of fictive swimming at both developmental stages, including a reduction in swimming frequency and episode duration, along with a significant reduction in motor burst amplitude and duration in larval animals only. Applications of selective antagonists provide evidence for activation of all three groups during swimming. The group II and III antagonists EGLU (1-ethyl-2-benzimidazolinone) and MAP4 [(S)-2-amino-2-methyl-4-phosphonobutanoate], respectively, increased, while group I antagonists, CPCCOEt and MPEP, decreased swim frequency. Our findings thus provide evidence for the presence and endogenous activation of three classes of metabotropic glutamate receptor which may function as an intrinsic modulatory control system during fictive swimming in Xenopus tadpoles.
Chapman
Rebecca J
RJ
School of Biology, Bute Medical Buildings, University of St. Andrews, St. Andrews, Fife KY16 9TS, UK.
Sillar
Keith T
KT
D000200:Action Potentials / Q000502:physiology; D000613:Aminobutyrates / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D004625:Embryo, Nonmammalian; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005971:Glutamates / Q000494:pharmacology; D066298:In Vitro Techniques; D007814:Larva / Q000187:drug effects / Q000502:physiology; D008124:Locomotion / Q000187:drug effects / Q000502:physiology*; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000494:pharmacology; D009415:Nerve Net / Q000502:physiology*; D010507:Periodicity; D010812:Physical Stimulation / Q000379:methods; D018094:Receptors, Metabotropic Glutamate / Q000502:physiology*; D013116:Spinal Cord / Q000166:cytology*; D013550:Swimming; D013997:Time Factors; D014982:Xenopus laevis
C117789:7-(hydroxyimino)cyclopropan(b)chromen-1a-carbxoylic acid ethyl ester; D000613:Aminobutyrates; D002867:Chromones; D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D005971:Glutamates; D018094:Receptors, Metabotropic Glutamate; C017302:alpha-ethylglutamic acid; D008734:Methoxyhydroxyphenylglycol; C012729:2-amino-4-phosphonobutyric acid; C010117:3,4-dihydroxyphenylglycol